Hepatic arterial infusion in liver tumors of unknown, uncertain or unusual primary: single-center experience
Language English Country Cyprus Media print
Document type Clinical Trial, Journal Article
PubMed
30941963
Knihovny.cz E-resources
- MeSH
- Hepatic Artery * MeSH
- Adult MeSH
- Fluorouracil administration & dosage MeSH
- Infusions, Intra-Arterial * MeSH
- Leucovorin administration & dosage MeSH
- Middle Aged MeSH
- Humans MeSH
- Survival Rate MeSH
- Liver Neoplasms drug therapy mortality secondary MeSH
- Neoplasms drug therapy mortality pathology MeSH
- Follow-Up Studies MeSH
- Prognosis MeSH
- Antineoplastic Combined Chemotherapy Protocols administration & dosage MeSH
- Retrospective Studies MeSH
- Aged MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Clinical Trial MeSH
- Names of Substances
- Fluorouracil MeSH
- Leucovorin MeSH
PURPOSE: The aim of the present study was to analyze a single-center experience with hepatic arterial infusion (HAI) in patients with unknown or uncertain primary or tumors not usually treated with HAI. METHODS: A retrospective analysis of 14 patients treated between 1996 and 2003 for liver tumors of unknown, uncertain or unusual primary was performed. RESULTS: All patients were treated with HAI combination regimens based on 5-fluorouracil and folinic acid. The response was not evaluable in most patients, predominantly because of only a single course of therapy could be administered and no cases of partial or complete response were noted. The median survival of all patients was 6.6 months (5-year survival 14%). CONCLUSION: The present data demonstrate limited efficacy of HAI in patients with liver tumors of unknown, uncertain or unusual primary. HAI should not be offered to these patients.
